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Abstract
Background: Celiac disease (CD) emerged as a public health problem, and the disease prevalence varies among
different races. The present study was designed to investigate the prevalence of CD using serological markers in
apparently healthy schoolchildren in Irbid City, Jordan. Additionally, the effect of positive serology on height,
weight and body mass index (BMI) was evaluated.
Methods: The study population consisted of 1985 children (1117 girls and 868 boys), age range was 5.5 to 9.5
years. Height and weight were measured and blood samples were collected from each individual. Serum samples
were analyzed for IgA anti-tissue transglutaminase antibodies (tTG) using a commercial enzyme-linked
immunosorbent assay (ELISA). tTG positive samples were further analyzed for IgA anti-endomysium antibodies
(EmA) with a commercial ELISA. Samples confirmed positive with EmA were considered seropositive.
Results: Sixteen children were CD positive. The serological prevalence was estimated to be 1:124 (0.8%; 95% CI,
0.5% to 1.3%). Significant impact on growth (height) was found in seropositive children. When both sexes were
individually analyzed, only boys showed height reduction. Furthermore, seropositive boys also had a significant
weight reduction.
Conclusion: This study demonstrated that CD is prevalent among schoolchildren in Jordan. The seropositive
children tend to have lower height, weight, and BMI than the seronegative group. These differences were
significant only for boys. None of the participants is known to have CD prior to the study.
Background
Celiac disease (CD) is an immune-mediated small-bowel
enteropathy. The disease is triggered by ingestion of glu-
ten containing diet such as wheat, barley, and rye in
genetically susceptible individuals [1]. Globally, the DQ2
type II human leukocyte antigen (HLA) is found in 90-
95% of individuals suffering from CD. The remaining
5%, express the HLA-DQ8 variant [2]. The pathological
features are a typical flat mucosa, abnormal surface
epithelium, villous atrophy and hyperplastic crypts in
the small intestine. The 1990 European Society for
Pediatric Gastroenterology and Nutrition (ESPGAN) cri-
teria for the diagnosis of CD require typical intestinal
mucosa alterations [3]. Resolution of histological
changes or symptoms is needed as a response to a strict
gluten free diet (GFD) [4].
CD is a disease with a wide spectrum of manifesta-
tions, ranging from no apparent effect, to chronic diar-
rhea, abdominal distention, muscle wasting, hypotonia,
poor appetite and distress (Table 1) [5]. Mortality and
morbidity in CD patients are modestly increased com-
pared to the general population [6]. Several studies have
reported reduced growth in seropositives [7,8]. The only
known cure for CD is a strict, lifelong adherence to
GFD [9,10].
Serological screening is simple; it provides prevalence
close to the biopsy proven CD prevalence. Serological
evidence of CD has been reported to be 0.3-1.4% in
population-based screening studies in a number of
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based on clinical symptoms has been estimated to be
between 1: 1000 and 1: 10000 [10]. Serological screening
studies have altered the perception of CD from a rare
disorder, into a rather common condition.
Serological screening for CD has not yet been carried
out in Jordan, and CD is not a common diagnosis
among children in Jordan [15]. The aim of this study
was to estimate the prevalence of CD using serological
markers among a group of children aged 5.5 to 9.5 years
in Irbid City, and to compare height, weight, and body
mass index (BMI) in the seropositive group to the sero-
negative group.
Methods
This is a collaborative-research study between the Nor-
wegian University of Science and Technology (NTNU)
and the Jordan University of Science and Technology
(JUST).
Children in 20 elementary schools, grade one to four,
in Irbid City, Jordan, were invited to participate in the
study. Selection of schools was random. Eighteen
schools were public and two were private. Both urban
and rural areas were covered and socioeconomic status
varied. None of the participants was reported to have
CD. Twenty-four children 10 - 12 years old were
excluded because they were too old. The study popula-
tion consisted of 1985 children (1117 girls) age 5.5 - 9.5
years; mean, 8 years. According to the Registry and
Statistical Department in Jordan, Irbid City had 54592
inhabitants between 6 and 10 years at the time of the
study.
The study was approved by the Ministry of Health, the
Ministry of Education in Jordan and the ethical commit-
tee of JUST. The study was performed according to the
ethical standards for human research of the Helsinki
Declaration [16]. Parents or legal guardians of partici-
pants were asked to provide a written consent.
Collection of blood samples, information and mea-
surements were performed in schools between October
11
th and November 5
th 2006. Information about age,
sex, and a possible former CD diagnosis were also col-
lected. All height and body weight measurements were
performed by one researcher.
Serum samples were analyzed in duplicates for IgA
antibodies to human tissue transglutaminase (tTG)
using enzyme linked immunosorbent assay (ELISA)
(Orgentec Diagnostika GmbH, Mainz, Germany). The
test has a lower detection limit of 1.0 U/ml and 10 U/
ml was the cut-off point for positive result. Positive
samples for tTG antibodies were reanalyzed for confor-
mation. Positive results were further analyzed with a
commercial ELISA for IgA autoantibodies to human
endomysial autoantigens (EmA) (GA Generic Assays
G m b H ,D a h l e w i t z ,G e r m a n y ) .The analytical sensitivity
of this test was 3 U/ml and the cut-off value was 20 U/
ml. ELISA-tests were performed manually at King
Abdullah University Hospital, JUST using an automatic
Table 1 Reasons for serological testing and grouping of celiac disease (CD) by symptoms (Fasano 2005, Rostom et al
2004).
Classical CD Atypical CD Silent CD
Reasons for testing: Investigation of intestinal symptoms. Iron deficiency, osteoporosis, short stature, or infertility. Screening.
Symptoms: Intestinal symptoms. Unusual intestinal complaints or extraintestinal manifestations. Asymptomatic.
Table 2 Results of different screening studies for celiac disease, CD
Country Age (years) Number Antibody* Prevalence Reference
United Kingdom 7.5 5470 1. tTG
2. IgA EmA
1:101
(1.0%)†
(Bingley et al 2004)
The Netherlands 2 to 4 6127 1. IgA EmA 1:82 (1.2%)‡ (Csizmadia et al 1999)
The USA 2 to 18 1281 1. IgA EmA 1:320
(0.3%)§
(Fasano et al 2003)
Finland 7 to 16 3654 1. IgA EmA and IgA
tTG
1:73 (1.4%)|| (Maki et al 2003)
Turkey Adult blood
donors
2 000 1. IgA tTG 1:87 (1.1%)‡ (Tatar et al 2004)
North America and Western
Europe
Children Large
population
Biopsy 0.5% to
1.6%.
AHRQ No. 104 Celiac Disease
2004
tTG: tissue transglutaminase; EmA; anti-endomysium antibody.
*: 1. = the test(s) performed as screening test(s). 2. = the test performed for confirmation of the screening test.
† The prevalence is based on subjects confirmed positive with a second serological marker.
‡ The prevalence is based on subjects positive on only one serological marker.
§The prevalence is based on one serological marker (IgA EmA), but all tested positive on IgA tTG as well.
|| Two tests were carried out at the same time, and the serological prevalence is based on subjects positive on both tests.
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Page 2 of 6washer (ELx 50 Auto Strip washer, Bio-Tek Instruments
NC) and a Bio-Rad Eliza reader (680 Model), Bio-Rad
Laboratories, UK. EmA positive subjects were defined as
t h es e r o p o s i t i v eg r o u p( n=1 6 ) ,w h i l et h er e s to ft h e
study population constituted the seronegative group (n
= 1969) (Figure 1).
Subjects were divided into different age groups using
half-year as accuracy level. Mean age and sex distribu-
tion were found in the whole study population and the
serological prevalence of CD was calculated. The 95%
confidence interval (95% CI) of the estimated prevalence
was computed by the Agresti-Coull method:
   pp p n  19 6 1 .( ( () ) / ) . 
  px n  n n    () / . . 24
x = number of seropositives. n = number in the study
population.
Regression analysis was used to compare the measure-
ments and BMI in the seropositive group with the
values in the seronegative group. This approach gave
age- and sex-adjusted estimates. The value of interest,
for instance height, was entered as dependent variable.
Covariates were age, sex, and seropositive group. The
significance of interactions between the two covariates
sex and seropositive group was tested for each value of
interest. A separate regression analyses for each sex on
each dependent variable was performed. With age and
seropositive group as covariates, age-adjusted estimates
were obtained. A two-sided P < 0.05 was considered sig-
nificant. Analyses were performed using SPSS 13.0 for
Windows.
Results
Among the 1985 children, 16 were seropositive, of those
9 were girls; median age was 8 years and the age-range
was 6 to 9.5 years (Figure 1). The serological prevalence
of CD in this population is 1:124 (0.8%; 95% CI, 0.5% to
Figure 1 Flowchart for procedure and results of serological screening for celiac disease among schoolchildren in Irbid city, Jordan.
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Page 3 of 61.3%). The ratio between both sexes was equal in the
study population and the seropositive group.
Seropositive group tends to have lower height, weight,
and BMI than the seronegative group, but the difference
was only significant for height (P =0 . 0 2 7 ) .T h ed i f f e r -
ence for BMI (P = 0.217) was not significant whereas
for weight, but it was very close to significance (P =
0.055). There were no significant differences between
both sexes, neither regarding height (P =0 . 0 7 9 ) ,w e i g h t
(P =0 . 2 0 2 ) ,n o rB M I( P = 0.502). The growth para-
meters in the seropositive boys were generally lower
than those in the seropositive girls. The seropositive
boys were significantly shorter (P = 0.014) and lighter (P
= 0.015) than seronegative girls, but BMI values were
not significantly lower (P = 0.078). Differences were not
significant when comparing seropositive girls with sero-
negative girls, for height (P =0 . 9 1 9 ) ,w e i g h t( P =0 . 4 1 4 )
and BMI (P = 0.330).
Discussion
The worldwide serological prevalence of CD ranges
from 0.3% to 1.4% (Table 2) [7,11-14] and the CD pre-
valence of this study is in agreement with previous
screening studies. Study-designs have shown variability
in population studied, population size, testing proce-
dures, definition of seropositive result, and which serolo-
gical test the estimated prevalence is based on. These
discrepancies contributed to the variability of reported
prevalence. AHRQ reported a prevalence of CD in chil-
dren by biopsy of 0.5% to 1.6% [17].
Our results as well as other studies have demonstrated
that growth parameters are affected in CD seropositive
group [7,8]. Discrepancies in study design and popula-
tion, make it difficult to compare those findings with
ours. In a study by Hoffenberg et al 2004, tTG-positive
children have reduced z-scores for weight-for-height
(-0.3 ± 0.7 vs. 0.3 ± 1; P = 0.02) and BMI (-0.3 ± 0.7 vs.
0.4 ± 0.9; P < 0.01) compared to controls, but did not
show significant changes concerning weight- or height-
for-age. Since two concordant serological markers were
used to define the seropositive group in our study, it is
likely to assume that a higher percentage of our seropo-
sitive group will be diagnosed with CD than in the
study by Hoffenberg et al 2004.
The Agency for Healthcare Research and Quality
(AHRQ) report found a prevalence of CD in children by
biopsy of 0.5% to 1.6% and by serology of 0.3% to 1.9%
[17]. Even though, the gold standard for the diagnosis of
CD is duodenal biopsy, recent reports have shown that
tTG alone is a sensitive marker for CD, yet noninvasive
[18]. tTG is the marker of choice for CD mass screening
and helpful in identifying patients who can benefit from
gluten free diet and follow-up [19,20].
Another study used a two-step approach to define the
seropositive group, found that seropositive children
were lighter by 0.54 z-scores and shorter by more than
0.76 z-scores than seronegative controls [7]. Similarly,
we found significant height reduction in the seroposi-
tives compared to controls. They also reported that ser-
opositive children weighed significantly less than the
controls. This also seems to be a trend in our study,
although not significant (P = 0.055). Nonetheless, Bing-
ley et al 2004, reported a study population of 5470 with
54 seropositive individuals. With a larger seropositive
group, significant differences would more likely be pre-
sent. Interestingly, the trend we see in weight reduction
s e e m st ob ei na c c o r d a n c ew i t ht h es t u d yb yB i n g l e y
and coworkers.
The serology test results can be interpreted in differ-
ent ways. We have chosen a two-step approach, where
positive tTG was confirmed with positive EmA. Com-
bining tests yield a higher positive predictive value
( P P V )a tt h ee x p e n s eo fm i ssing some single marker
positive patients [21]. If we consider only tTGA positiv-
ity as sufficient, the estimated prevalence in our study
w o u l dr i s et o1 : 6 6( 1 . 5 % ;9 5 %C I ,1 . 1 %t o2 . 2 % ) .T h i s
approach gives an increased sensitivity at the cost of
specificity.
The positive predictive value (PPV) and negative pre-
dictive value (NPV) of a test result depend on the preva-
lence of the disease in the population tested. We
performed screening on healthy children, where the pre-
valence of CD is low compared to a population with
suspected CD. The PPV of a positive serology test drops
as CD prevalence decreases [2]. As PPV falls, the risk of
false positive CD patients increases. Because of the low
prevalence of CD in our population, we required two
concordant tests to improve PPV. NPV and CD preva-
lence demonstrate the reverse relationship as PPV and
CD prevalence [2]. With a low CD prevalence in the
population tested, NPV of the serological tests is high.
In a study, 31 of 57 children positive for IgA EmA had
biopsies compatible with CD [11]. This means that the
test’s PPV was 54.4%. In the study by Hoffenberg et al
2004, the PPV of the tTG test was 72.2%. In another
study the PPV was 82.9%, in the group which tested
positive for both EmA and tTG [13]. This supports that
PPV improves with two concordant tests.
Selective IgA deficiency is associated with CD patients
[22]. CD patients with IgA deficiency do not express the
IgA-type antibodies. A screening study among children
found the prevalence of both CD and IgA deficiency to
be 1:1218 [13]. This indicates that the combination is
rare in asymptomatic children. In contrast, IgA defi-
ciency occurs in about 2% of the symptomatic CD chil-
dren [23]. Therefore, IgA deficiency must be considered
in the assessment of symptomatic patients. According to
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serum IgA levels or adding IgG-based serology as part
of a panel to screen asymptomatic individuals in the
general population is not warranted.” We may, however,
have missed CD patients with IgA deficiency [24].
Our serological prevalence is a close estimate of CD in
the population. The study may have false positive and
false negative CD cases because the correlation between
serological markers and small bowel biopsy is not 100%.
Furthermore, false seropositives may represent a source
of error when comparing growth parameters.
Even though, screening may detect silent CD, clinical
benefits of identifying all cases of CD remain controver-
sial [8]. To justify population-based screening, advan-
tages should outweigh the disadvantages of being
diagnosed with CD. A screening study performed in
Italy found that two thirds of the biopsy proven CD
were asymptomatic [25].
Our study has shown that CD is a common disorder
in Jordan and physicians must consider CD in patients
presenting a wide range of clinical symptoms.
Conclusion
A serological prevalence of 1:124 (0.8%) indicates that
CD is a common disorder among schoolchildren in Jor-
dan. It demonstrates that Jordanian physician should
have a high index of suspicion for CD. The serological
prevalence found in this study is in accordance with the
results of similar studies. In the seropositive group a
tendency to lower height, weight, and BMI than in the
seronegative group was found, but the difference was
only significant for height. The seropositive boys tended
to be more growth-affected than the seropositive girls,
but the differences between the sexes were not signifi-
cant. This study underscores that Jordanian physician
should have a low threshold for suspecting CD.
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